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Abstract : The placebo effect, or response, is a complex phenomenon whereby an inert treatment 
can induce a therapeutic benefit if the subject is made to believe that it is effective. One of the main 
mechanisms involved is represented by expectations of clinical improvement which, in turn, have 
been found to either reduce anxiety or activate reward mechanisms. Therefore, the study of the 
placebo effect allows us to understand how emotions may affect both behavior and therapeutic 
outcome. The high rate of placebo responders in clinical trials of Parkinson's disease provided the 
motivation to investigate the biological underpinnings of the placebo response in Parkinsonian 
patients. The placebo effect in Parkinson's disease is induced through the administration of an inert 
substance which the patient believes to improve motor performance. By using this approach, 
different behavioral and neuroimaging studies have documented objective improvements in motor 
performance and an increase of endogenous dopamine release in both the dorsal and ventral 
striatum. Recently, single-neuron recording from the subthalamic and thalamic regions during the 
implantation of electrodes for deep brain stimulation has been used to investigate the firing pattern 
of different neurons before and after placebo administration. The results show that the subthalamic 
nucleus, the substantia nigra pars reticulata, and the ventral anterior thalamus are all involved in the 
placebo response in Parkinson patients, thus making intraoperative recording an excellent model to 
characterize the neuronal circuit that is involved in the placebo response in Parkinson's disease as 
well as in other disorders of movement. 
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1. Introduction 
In recent years, the placebo effect, or response, has evolved from a nuisance in the setting of 
clinical trials to a topic worthy of scientific inquiry. The placebo response is a change in the body, 
or the body-mind unit, that occurs as a result of the symbolic significance which one attributes to an 
event or object in the healing environment (Brody, 2000). Considerable progress has been made in 
our understanding of its neurobiological mechanisms, particularly in conditions such as pain and 
Parkinson's disease. Other medical conditions, like depression, anxiety, hormone secretion, immune 
functions and addiction, are less understood, yet some of their neurobiological mechanisms have 
been identified as well (Benedetti, 2008). Today we know that the placebo effect is due to the 
psychosocial context surrounding the patient and the therapy (Benedetti et al., 2011a and Colloca 
and Benedetti, 2005). In fact, different sensory and social stimuli, which constitute the ritual of the 
therapeutic act, can induce positive expectations of clinical improvement. The link between 
expectations and any effect that may take place in the brain and body is represented by at least a 
twofold mechanism. First, expectation of a positive outcome may reduce anxiety (Petrovic et al., 
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2005 and Vase et al., 2005) and second, it can activate reward mechanisms, whereby the reward is 
the therapeutic benefit itself (de la Fuente-Fernández et al., 2001 and Scott et al., 2007). Therefore, 
the study of the placebo effect is a window that allows us to understand how emotions may affect 
both behavior and therapeutic outcome. Indeed, anticipation of either a positive or negative event, 
which involves its appraisal, has been postulated to take part in emotions (Scherer, Schorr, & 
Johnstone, 2001). 
Most of our knowledge about the neurobiological mechanisms of the placebo effect comes 
from the field of pain and analgesia (Benedetti, 2008). It is well established that different 
endogenous neuronal networks are responsible for the modulation of pain by placebos. In particular, 
the activation of the descending pain-modulating network from the cerebral cortex to the brainstem 
and spinal cord has been described, with the involvement of opioid, cannabinoid, cholecystokinin 
and dopamine systems (Benedetti, 2008, Benedetti et al., 2011a and Tracey, 2010). What has 
emerged over the past few years is that the endogenous opioids and endocannabinoids are involved 
in placebo analgesia in different circumstances (Benedetti, Amanzio, Rosato, & Blanchard, 2011) 
whereas cholecystokinin plays a key role in the opposite effect, namely, nocebo hyperalgesia 
(Benedetti, Amanzio, Vighetti, & Asteggiano, 2006). In this sense, the nocebo response is a 
phenomenon opposite to the placebo response that is due to the negative symbolic significance 
which one attributes to an event or object in the healing environment. 
Besides pain and analgesia, there is extensive evidence for a prominent placebo effect in 
Parkinson's disease (see below), which makes this motor disorder an excellent condition to 
investigate (Benedetti, 2008). There are at least two other reasons why Parkinson's disease is a good 
model for placebo studies. First, differently from pain, in Parkinson's disease the response to 
treatment can be assessed objectively by the experimenter, thus providing objective measurements 
of motor performance. Second, the use of electrodes for deep brain stimulation offers the 
opportunity to analyze the placebo response at the unprecedented level of single-neuron recording 
in awake patients, thus allowing us to perform a correlation between the clinical outcome and the 
activity of single neurons in different brain regions. 
 
2. The placebo response in Parkinson patients 
Parkinson's disease is mainly a disorder of movement, although several sensory, cognitive, 
mood, sleep, autonomic disturbances may be present as well (Blandini et al., 2000 and McRae et al., 
2004). There are at least three important motor symptoms: tremor, rigidity, and bradykinesia. 
Tremor is at rest and involves mainly the upper limbs, although other body parts may be subject to 
tremor, such as the chin. Rigidity involves all the muscles, with a global impairment of movements 
and gait. Bradykinesia means that movements slow down, so that any action is performed very 
slowly and with difficulty. 
Substantial improvements in Parkinsonian symptoms are seen in placebo groups of many 
clinical trials that assess both pharmacological and surgical treatments for Parkinson's disease 
(Diederich and Goetz, 2008, Galpern et al., 2012, Goetz et al., 2002, Goetz et al., 2008a, Goetz et 
al., 2000 and Shetty et al., 1999). Interestingly, the side effects of pharmacological therapy, such as 
dyskinesia, were found to be evoked by placebo treatments as well (Goetz, Laska, et al., 2008). 
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Substantial improvements in motor symptoms are also present in patients who are assigned to the 
placebo group in surgical treatments of Parkinson's disease (Gill et al., 2003, Gross et al., 2011, 
Lang et al., 2006, Marks et al., 2008, Marks et al., 2010, Olanow et al., 2003, Slevin et al., 2005 and 
Stover et al., 2005). However, it should be noted that these trials are usually aimed at comparing 
active treatments versus placebos, with no natural history groups. Therefore, the clinical 
improvements in the placebo groups cannot be attributed to real psychobiological placebo effects 
only, as spontaneous remission and regression to the mean are taking a part in the reduction of the 
symptoms in many cases. Nonetheless, the high rate of placebo effects in clinical trials of 
Parkinson's disease provided the impetus to investigate placebo responses of Parkinson patients in 
more detail and under strictly controlled conditions. 
In order to overcome these limitations in the clinical trials setting, Parkinson patients have 
been studied under strictly controlled conditions with a rigorous experimental approach, whereby 
the placebo group is compared to a natural history group, in order to rule out spontaneous 
remission. In a typical placebo procedure in Parkinson patients, a placebo is administered along 
with verbal suggestions of motor improvement, so that the patients expect an improvement in their 
motor symptoms, such as tremor, muscle rigidity, and bradykinesia. For example, the velocity of 
movements in Parkinson patients who had been implanted with electrodes in the subthalamic nuclei 
for deep brain stimulation was analyzed in the laboratory setting (Pollo et al., 2002). In order to 
manipulate the patients' expectations, two opposite conditions were studied. In the first condition, 
the patients were told that the intensity of stimulation was high, so that they expected good motor 
performance, whereas in the second they were told that the stimulation intensity was lowered, so as 
to induce expectations of bad motor performance. The effect of subthalamic stimulation on the 
velocity of movement of the right hand was analyzed with a movement analyzer, which was 
characterized by a rectangular surface where the patients performed a visual directional-choice task. 
To do this, the right index finger was positioned on a central sensor with a green light. After a 
random interval of a few seconds, a red light turned on randomly in one of the three sensors placed 
10 cm away from the green-light sensor. The patients were instructed to move their hand as quickly 
as possible in order to reach the target red-light sensor. The hand movement was found to be faster 
when the patients expected a good motor performance than when they expected bad performance. 
Interestingly, all these effects occurred within minutes, which indicates that expectations of clinical 
improvement induce neural changes very quickly. Similar findings were confirmed in subsequent 
studies (Benedetti et al., 2003 and Mercado et al., 2006). 
The important role of expectations is further supported by a clinical trial of human fetal 
mesencephalic transplantation (McRae et al., 2004). Besides the classical clinical trial approach, 
these investigators also assessed the patient's perceived assignment to either the active (fetal tissue 
implant) or placebo treatment (sham surgery). There were no differences between the transplant and 
sham surgery groups on several outcome measures, such as physical and quality of life scores. 
However, the perceived assignment of treatment group had a beneficial impact on the overall 
outcome and this difference was still present at twelve months after surgery. Patients who believed 
they received transplanted tissue had significant improvements in both quality of life and motor 
outcomes, regardless of whether they received sham surgery or fetal tissue implantations. 
Therefore, the expectation of therapeutic benefit represents one of the main factors that mediates the 
placebo response in Parkinson's disease (Keitel et al., 2013). 
4 
 
 
3. Dopamine and the placebo response 
The disruption of dopamine function in the neural pathway from the substantia nigra pars 
compacta to the striatum (putamen and caudate nucleus) represents the pathophysiological substrate 
of Parkinson's disease. The primary deficit involves the selective degeneration of the nigrostriatal 
dopamine-producing neurons, although at later stages of the disease, other dopamine projections 
and other neurotransmitters may also be affected. There are in fact different dopaminergic pathways 
in the brain, such as the mesocortical, the mesolimbic, and the tuberoinfundibular. These pathways 
are associated with volition and emotional responsiveness, desire and reward, and sensory processes 
and maternal behavior. The neuropsychiatric pathology associated with Parkinson's disease is 
attributable to the loss of dopamine along the non-striatal pathways. As far as the motor system is 
concerned, dopamine has a critical role in the modulation of the basal ganglia functioning 
(Alexander et al., 1986 and Haber, 2003), and its depletion results in difficulties initiating 
movement (akinesia), bradykinesia (slowness of movement), rigidity, tremor at rest, and postural 
instability. 
By using positron emission tomography, de la Fuente-Fernández et al. (2001), de la Fuente-
Fernández, Schulzer, and Stoessl (2002) and de la Fuente-Fernández, Phillips, et al. (2002) found 
that placebo administration induces the activation of the dopaminergic system in Parkinson patients 
(Fig. 1). The release of dopamine in the motor striatum (putamen and dorsal caudate) was greater in 
those patients who reported clinical improvement. Although all patients showed dopamine placebo 
responses, only half of the patients reported motor improvement. These patients also released larger 
amounts of dopamine in the dorsal motor striatum, suggesting a relationship between the amount of 
dorsal striatal dopamine release and clinical benefit. This relationship was not present in the ventral 
striatum, in which all patients showed increased dopamine release, irrespective of whether they 
perceived any improvement. Compared to the dorsal motor striatum, the ventral striatum (nucleus 
accumbens) is involved in motivation and reward anticipation (Ikemoto and Panksepp, 1999, 
Knutson and Cooper, 2005, Schultz, 2002 and Schultz et al., 2000). Accordingly, de la Fuente-
Fernández et al., 2001 and de la Fuente-Fernández et al., 2002a and de la Fuente-Fernández, 
Phillips, et al. (2002) proposed that the dopamine released in the ventral striatum was associated 
with the patients' expectation of improvement in their symptoms, which could in turn be considered 
a form of reward. This finding was confirmed by Strafella, Ko, and Monchi (2006) in Parkinson 
patients and by Scott et al. (2007) in pain. 
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4. Characterization of the neuronal circuit through intraoperative recording 
Following the finding of a placebo-induced dopamine release, Benedetti et al. (2004) started 
looking for possible neuronal changes in different regions of the basal ganglia by using single-
neuron recording in awake patients. Indeed, the subthalamic nucleus is now the major target in the 
surgical therapy of Parkinson's disease and its identification can require the recording of electrical 
activity in the subthalamic nucleus (Hutchison et al., 1998). Therefore, the activity of single neurons 
in the subthalamic nucleus as well as in the surrounding regions can be recorded in different 
conditions, for example after the administration of a pharmacological agent. Several studies have 
reported that the anti-Parkinson agent, apomorphine, induced changes in the subthalamic nucleus 
firing pattern of patients with Parkinson's disease (Levy et al., 2001, Lozano et al., 2000 and Stefani 
et al., 2002). Although Levy et al. (2001) found a certain variability in the firing rates of single 
neurons under the effect of apomorphine, Stefani et al. (2002) reported that the administration of 
apomorphine is invariably followed by a reduction of firing rate from about 40 to about 27 Hz. 
According to the classic pathophysiological view of Parkinson's disease, the dopamine 
depletion in the striatum induces both hyperactivity (high firing rate) (Blandini et al., 2000) and 
bursting activity (Bergman et al., 1994 and Levy et al., 2001) of subthalamic nucleus neurons. This 
might be due to a lower activity of the external globus pallidus which sends inhibitory projections 
to the subthalamic nucleus (see Fig. 1 for the main basal ganglia connections). Therefore, the 
external globus pallidus hypoactivity would result in decreased inhibition upon the neurons of the 
subthalamic nucleus. The high-frequency therapeutic stimulation of the subthalamic nucleus would 
modify this abnormal activity (Limousin et al., 1997), and this might be achieved through the 
stimulation of the inhibitory afferents from the external globus pallidus to the subthalamic nucleus. 
Other mechanisms have also been hypothesized (Benedetti, 2008). 
On the basis of these pathophysiological considerations, in 2004, the first study of the placebo 
effect at the single-neuron level was performed by Benedetti et al. (2004). Since the subthalamic 
nucleus plays an essential role in basal ganglia functioning and is a major target in the surgical 
therapy of Parkinson's disease (Limousin et al., 1997) and, in addition, its identification requires the 
recording of intranuclear electrical activity in awake Parkinson patients, these authors performed a 
double-blind study in which the activity from single neurons in the subthalamic nucleus before and 
after placebo administration was recorded to see whether neuronal changes were associated to the 
clinical placebo response. In order to make the placebo response stronger, the placebo was 
administered in the operating room after several pre-operative administrations of the anti-
Parkinsonian drug apomorphine (pharmacological pre-conditioning procedure). 
Before placebo administration, the activity of neurons was recorded from one subthalamic 
nucleus prior to implantation of the first electrode and used as a control. After the placebo, which 
consisted of a subcutaneous injection of saline solution along with the verbal suggestion of motor 
improvement, neuronal activity was recorded from neurons prior to implantation of the second 
electrode into the other subthalamic nucleus. A placebo response was defined as the decrease of arm 
rigidity of at least 1 point on the clinical evaluation scale. Those patients who showed a 
straightforward clinical placebo response, assessed by means of arm rigidity and subjective report 
of well-being, also showed a significant decrease of firing rate compared to the pre-placebo 
subthalamic nucleus. In order to rule out the possibility that the difference in firing rate between the 
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pre- and post-placebo subthalamic nucleus was independent of the placebo treatment itself, a no-
treatment group (natural history) was studied. The patients of this no-treatment group did not 
undergo any placebo treatment between the implantation of the first and second electrode. All these 
patients showed no significant differences between the neuronal firing rates of the two subthalamic 
nuclei, which indicates that the difference between the first and the second side of implantation in 
the placebo group was due to the placebo intervention per se. It is also important to point out that 
the clinical placebo response was assessed before lowering the electrode tip into the subthalamic 
nucleus, in order to avoid the possible microlesional effects of the electrode, which might represent 
a confounding factor. 
Although the mean firing rate is a good parameter to assess the activity of the subthalamic 
nucleus, bursting and oscillatory patterns have also been described in Parkinson's disease and 
related to motor symptoms and to apomorphine effects (Bergman et al., 1994 and Levy et al., 2001). 
Therefore, in the single-neuron analysis by Benedetti et al. (2004), the bursting activity of the 
subthalamic nucleus neurons before and after placebo administration was also investigated, in order 
to see whether, beside the frequency decrease, there was also a change in the pattern of discharge. It 
was found that the subthalamic nucleus neurons of all the placebo responders shifted significantly 
from a pattern of bursting activity to a pattern of non-bursting discharge. All the placebo non-
responders did not show any difference in the number of bursting neurons before and after placebo 
administration. Likewise, the no-treatment group did not show any significant difference in bursting 
activity between the first-side and second-side subthalamic nucleus. 
In the study by Benedetti et al. (2004) there was a correlation between subjective reports of 
the patients, clinical responses and neurophysiological responses. In fact, a decrease in firing rate as 
well as a change from bursting to non-bursting activity of subthalamic nucleus neurons was 
correlated with both the patients' subjective reports of well-being and the muscle rigidity reduction 
at the wrist, as assessed by a blind neurologist. Although it is tempting to speculate that these 
neuronal changes represent a downstream effect of dopamine release in the striatum, the dopamine 
release in the striatum (de la Fuente-Fernández et al., 2001) and the single-neuron changes 
(Benedetti et al., 2004) were observed in two different studies, thus no definitive conclusion can be 
drawn. Nonetheless, on the basis of our knowledge about the basal ganglia circuitry, it is plausible 
that a placebo-induced release of dopamine acting on the inhibitory D2 receptors disinhibits the 
gamma-aminobutyric acid (GABA) neurons of the external globus pallidus which, in turn, increase 
their inhibition onto the subthalamic nucleus (see Fig. 1 for a hypothesized model of the basal 
ganglia circuitry). 
In a more recent study, the same group extended the previous results on single-neuron 
recording in the subthalamic nucleus to two thalamic nuclei (ventral anterior - VA and anterior 
ventral lateral - VLa) and the substantia nigra pars reticulata (Benedetti et al., 2009). The 
subthalamic nucleus receives inputs from both the cortex and the external globus pallidus and sends 
excitatory output pathways to both internal globus pallidus (GPi) and substantia nigra pars reticulata 
(Fig. 1). Considering the effect of placebo administration on this nucleus (Benedetti et al., 2004), a 
significant placebo effect should also be expected in the subthalamic nucleus output regions. 
Indeed, in Parkinson patients who exhibited a clinical placebo response, the decrease in firing rate 
in the subthalamic nucleus was associated with a decrease in the substantia nigra pars reticulata and 
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